Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study-Reference-Cited by-同舟云学术

Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study

Published:2016-02 Issue:2 Volume:27 Page:314-318
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Lassalle A.,Thomaré P.,Fronteau C.,Mahé B.,Jubé C.,Blin N.,Voldoire M.,Dubruille V.,Tessoulin B.,Touzeau C.,Chauvin C.,Loirat M.,Lok A.,Bourcier J.,Lestang E.,Mocquet R.,Barbarot V.,Moreau P.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/2/314/6677149/mdv563.pdf

Reference7 articles.

1. Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study;Moreau;Lancet Oncol,2011

2. Subcutaneous versus intravenous bortezomib;Barbee;Ann Pharmacother,2013

3. International uniform response criteria for multiple myeloma;Durie;Leukemia,2006

4. Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the GMMG-MM5 trial;Merz;Haematologica,2015

5. Frontline therapy of multiple myeloma;Moreau;Blood.,2015

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. National expert consensus on home-administered oncologic therapies in Spain;Frontiers in Oncology;2024-02-16

2. The future of cancer care in the UK—time for a radical and sustainable National Cancer Plan;The Lancet Oncology;2024-01

3. Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting;The Breast;2023-12

4. Home infusion services in Saudi Arabia: Where are we standing?;Saudi Pharmaceutical Journal;2023-10

5. Autoinjectors for large-volume subcutaneous drug delivery: a review of current research and future directions;Expert Opinion on Drug Delivery;2023-06-03